Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Cervical Cancer Trial Results


Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
(Posted: 02/07/2013, Updated: 06/02/2013) - Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.

Second HPV Vaccine Shows Early Positive Results
(Posted: 07/17/2007, Updated: 12/02/2011) - The vaccine Cervarix® was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.

Treatment Regimen Extends Survival for Women with Cervical Cancer
(Posted: 06/29/2009, Updated: 10/20/2011) - Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.

New Data from HPV Vaccine Trials Available
(Posted: 05/22/2007) - Results from three years of follow-up data from two clinical trials of Gardasil, a vaccine that protects against the HPV viruses known to cause 70 percent of all cases of cervical cancer, have been published in the May 10, 2007, New England Journal of Medicine.

Related Pages